1. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
- Author
-
Dan Wang, Lan Fan, Chun-Ting Han, Li-Jun Yang, Yan-Mei Mao, Li-Hui Liu, Liang Peng, Hong-Hao Zhou, Dong Guo, Dong-Li Hu, Zhao-Qian Liu, and Zhi-Rong Tan
- Subjects
Male ,medicine.medical_specialty ,Genotype ,medicine.drug_class ,Cmax ,Proton-pump inhibitor ,CYP2C19 ,Pharmacology ,Placebo ,Gastroenterology ,Placebos ,chemistry.chemical_compound ,Pharmacokinetics ,Reference Values ,Internal medicine ,medicine ,Cytochrome P-450 CYP3A ,Humans ,Pharmacology (medical) ,Disulfides ,Chromatography, High Pressure Liquid ,Omeprazole ,Cross-Over Studies ,Allicin ,General Medicine ,Anti-Ulcer Agents ,Sulfinic Acids ,Crossover study ,Cytochrome P-450 CYP2C19 ,chemistry ,Spectrophotometry, Ultraviolet ,Aryl Hydrocarbon Hydroxylases ,medicine.drug - Abstract
To investigate the interaction between allicin and omeprazole and to observe the effects of allicin on CYP2C19 and CYP3A4 activity in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen subjects (six CYP2C19*1/CYP2C19*1, four CYP2C19*1/CYP2C19*2, two CYP2C19*1/ CYP2C19*3, and six CYP2C19*2/ CYP2C19*2) were enrolled in a two-phase randomized crossover trial. In each phase, all subjects received placebo or a 180 mg allicin capsule once daily for 14 consecutive days. The pharmacokinetics of omeprazole (20 mg orally on day 15) was determined for up to 12 h following administration by high-performance liquid chromatography. In carriers of the CYP2C19*1/CYP2C19*1 and CYP2C19*1/CYP2C19*2 or *3 genotype, allicin treatment increased the peak plasma concentration (Cmax) of omeprazole by 49.7 ± 7.2 (p
- Published
- 2009